Clinical trials for Anaplastic thyroid carcinoma
18 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT06790706IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersHospices Civils de Lyon
- RECRUITINGPhase 1NCT06902376XL092 and Cemiplimab in BRAF WT Thyroid CancerUNC Lineberger Comprehensive Cancer Center · PI: Siddharth Sheth, DO MPH
- RECRUITINGPhase 2NCT06235216Sacituzumab govitEcan in THYroid CancersGrupo Espanol de Tumores Neuroendocrinos · PI: Alejandro García-Alvarez, M.D.; Ph.D.
- RECRUITINGPhase 2NCT06362694Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF TherapySaint Petersburg State University, Russia
- RECRUITINGPhase 2NCT06374602Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerSaint Petersburg State University, Russia
- RECRUITINGPhase 2NCT06007924A Study of Avutometinib and Defactinib in People With Thyroid CancerMemorial Sloan Kettering Cancer Center · PI: Alan Ho, MD, PhD
- RECRUITINGPhase 2NCT06079333NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)Leiden University Medical Center · PI: Ellen Kapiteijn, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT05453799Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid CancerNorthwestern University · PI: Jochen H Lorch, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT05119296Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerStanford University · PI: Saad A Khan
- ACTIVE NOT RECRUITINGPhase 2NCT04171622Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerM.D. Anderson Cancer Center · PI: Maria E Cabanillas
- ACTIVE NOT RECRUITINGPhase 2NCT04675710Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerM.D. Anderson Cancer Center · PI: Mark Zafereo
- ACTIVE NOT RECRUITINGPhase 1NCT04420754Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid CancerAffyImmune Therapeutics, Inc. · PI: Sonal Gupta, MD PhD
- RECRUITINGPhase 1NCT03975231Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid CancerCity of Hope Medical Center · PI: Sasan Fazeli, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04238624Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerMemorial Sloan Kettering Cancer Center · PI: Eric Sherman, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05696548Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)National Cancer Center Hospital East · PI: Makoto Tahara, MD, PhD
- RECRUITINGNCT03765333GETNE Registration of Thyroid CancerGrupo Espanol de Tumores Neuroendocrinos · PI: Jorge Hernando Cubero, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT03449108LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasM.D. Anderson Cancer Center · PI: Amir A Jazaeri
- ACTIVE NOT RECRUITINGEarly Phase 1NCT03085056Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerMemorial Sloan Kettering Cancer Center · PI: Eric Sherman, MD